Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Health

>> PFIZER Latest News

AUG 29, 2014 - Yahoo! News

A Must Read - Share

Germany's Bayer to launch three new Xarelto trials

Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines. Xarelto, which competes with the Eliquis pill developed by Bristol-Myers Squibb and Pfizer in stroke prevention, reached sales of $1.7 billion in the 12 months to June. Bayer said on Friday that a Phase III ...

Tags: Germany's Bayer to launch three new Xarelto trials,  Pfizer Latest News

AUG 26, 2014 - Yahoo! News

A Must Read - Share

Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. Xalkori, which has annual sales of $400 million and is also known by its chemical name crizotinib, was approved in 2011 for lung cancer patients ...

Tags: Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,  Pfizer Latest News

AUG 21, 2014 - Reuters

A Must Read - Share

FDA approves use of Eliquis to treat leg, lung clots

(Reuters) - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

Tags: FDA approves use of Eliquis to treat leg, lung clots,  Pfizer Latest News

AUG 21, 2014 - Reuters

A Must Read - Share

FDA OKs use of Eliquis to treat leg, lung clots

(Reuters) - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

Tags: FDA OKs use of Eliquis to treat leg, lung clots,  Pfizer Latest News

AUG 21, 2014 - Yahoo! News

A Must Read - Share

Pfizer back for AstraZeneca? Year-end move seen most likely

By Ben Hirschler LONDON (Reuters) - Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds) takeover attempt in May. But while British takeover rules mean deal talks could be back on the cards as early as Aug. 26, following the ...

Tags: Pfizer back for AstraZeneca? Year-end move seen most likely,  Pfizer Latest News